An interventional study of Clozapine and Amisulpride in Schizophrenia and Treatment Resistant Disorders, sponsored by Geha Mental Health Center. Withdrawn at 1 site in Israel. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-12-09.
Sponsored by Geha Mental Health Center · Not applicable, Interventional, and Treatment
Background: schizophrenia is a debilitating mental disorder affecting about 1% of the general population. About 30% of patients will not react to current drug treatment and defined as treatment-resistant schizophrenia patients (TRSP). The best studied therapeutic option for this population is clozapine therapy. Clozapine was shown to be effective than any other antipsychotic drug in TRSP. Moreover, augmentation of clozapine was not demonstrated to be more effective than clozapine monotherapy. Albeit Clozapine superiority in TRSP, its use may be involved with many adverse effects, some of them are life-threatening, and need for routine blood tests. Amisulpride is an atypical antipsychotic drug with a different mechanism of action than clozapine, with less adverse effects. No study compared directly amisulpride and clozapine in TRSP.
Study objective: to compare, for the first time, the broad clinical effectiveness of clozapine and amisulpride and their combination in TRSP.
Study Design: a clinical, prospective, naturalistic, randomized, comparative study simulating a real-world approach of clinical decision making.
Methods: a total of 140 TRSP will be recruited from a large regional mental health center. Participants will be randomized into two treatment groups (70 in each group): clozapine monotherapy and amisulpride monotherapy. Assessment will be done following 10 and 20 weeks of treatment. In case of treatment failure (insufficient clinical response or severe adverse effect) participants will be offered either to switch to clozapine treatment (for failed amisulpride treatment) or to augment clozapine with amisulpride (for failed clozapine monotherapy patients). Thereafter, participants will be followed-up for a year. Assessment will be made using clinician rated scales and self-completed questionnaires, rating the broad phenomenology of schizophrenia (psychosis, mood, anxiety, obsessive-compulsive, cognitive and quality of life) and drug-related adverse effects (objective and subjective).
Analysis: comparison of the effectiveness of the three treatment groups: amisulpride, clozapine and their combination, in the various dimensions of TRSP.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
Browse Schizophrenia studies →Geha Mental Health Center is the lead sponsor of 8 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Clozapine monotherapy
Drug: Clozapine
Amisulpride monotherapy
Drug: Amisulpride
Augmentation of clozapine with amisulpride
Drug: Clozapine+Amisulpride
escalating dose of clozapine up to 900 mg/day
escalating dose of amisulpride up to 800 mg/day
augmentation of clozapine with amisulpride
Change from baseline in Positive and Negative Syndrome Scale (PANSS)
Time frame: 10, 20 weeks and endpoint
Change from baseline in Clinical Global Impression - Severity (CGI-S)
Time frame: 10 , 20 weeks and endpoint
Change from baseline in Beck Depression Inventory (BDI)
Time frame: 10 , 20 weeks and endpoint
Change from baseline in Beck Anxiety Inventory (BAI)
Time frame: 10, 20 weeks and endpoint
Change from baseline in Schizophrenia Quality of Life Scale (SQLS)
Time frame: 10, 20 weeks and endpoint
Change from baseline in Simpson-Angus Scale (SAS)
Time frame: 5, 10, 15, 20 weeks, endpoint
Change from baseline in Clozapine Adverse Effects Inventory (CAEI)
Time frame: 5, 10 ,15, 20 weeks, endpoint
This study is withdrawn, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Geha Mental Health Center